dbo:abstract
|
- TMC-647055 is an experimental antiviral drug which was developed as a treatment for hepatitis C, and is in clinical trials as a combination treatment with ribavirin and simeprevir. It acts as a NS5b polymerase inhibitor. (en)
|
dbo:casNumber
| |
dbo:chEMBL
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:pubchem
| |
dbo:thumbnail
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 3357 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:c
| |
dbp:casNumber
| |
dbp:chembl
| |
dbp:chemspiderid
| |
dbp:drugbank
| |
dbp:h
| |
dbp:iupacName
| |
dbp:legalUs
|
- Investigational drug (en)
|
dbp:molecularWeight
| |
dbp:n
| |
dbp:o
| |
dbp:pubchem
| |
dbp:s
| |
dbp:smiles
| |
dbp:stdinchi
| |
dbp:stdinchikey
|
- UOBYJVFBFSLCTQ-UHFFFAOYSA-N (en)
|
dbp:unii
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- TMC-647055 is an experimental antiviral drug which was developed as a treatment for hepatitis C, and is in clinical trials as a combination treatment with ribavirin and simeprevir. It acts as a NS5b polymerase inhibitor. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |